Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Jin-Ji Yang; Xu‐Chao Zhang; Jian Su; Chong‐Rui Xu; Qing Zhou; Hong-Xia Tian; Zhi Xie; Hua-Jun Chen; Yi-Sheng Huang; Ben‐Yuan Jiang; Zhen Wang; Bin-Chao Wang; Xue-Ning Yang; Wen‐Zhao Zhong; Qiang Nie; Ri-Qiang Liao; Tony Mok; Yi‐Long Wu

doi:10.1158/1078-0432.ccr-13-0699

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

ALK rearrangements and EGFR mutations could coexist in a small subgroup of NSCLC. Advanced pulmonary adenocarcinomas with such co-alterations could have diverse responses to EGFR-TKIs and crizotinib. Relative phospho-ALK and phospho-EGFR levels could predict the efficacy of EGFR-TKI and crizotinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2014) studied this question.

synapsesocial.com/papers/69de988b6bae133e7de9426d https://doi.org/10.1158/1078-0432.ccr-13-0699

View at Publisher

Ask AI

Bookmark

Share

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Ask about this paper

Abstract

Discussion

Cite This Study

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading